Eone Diagnomics Genome Center Co., Ltd.

KOSDAQ:A245620 Stock Report

Market Cap: ₩57.4b

Eone Diagnomics Genome Center Valuation

Is A245620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A245620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A245620's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A245620's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A245620?

Key metric: As A245620 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A245620. This is calculated by dividing A245620's market cap by their current revenue.
What is A245620's PS Ratio?
PS Ratio0.8x
Sales₩73.97b
Market Cap₩57.44b

Price to Sales Ratio vs Peers

How does A245620's PS Ratio compare to its peers?

The above table shows the PS ratio for A245620 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
A347740 P&K Skin Research Center
3.9xn/a₩62.8b
A359090 C&R Research
1.1xn/a₩65.8b
A036180 GW VitekLTD
1.6xn/a₩53.9b
A187660 Hyundai ADM Bio
6.6xn/a₩73.6b
A245620 Eone Diagnomics Genome Center
0.8xn/a₩57.4b

Price-To-Sales vs Peers: A245620 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2.3x).


Price to Sales Ratio vs Industry

How does A245620's PS Ratio compare vs other companies in the KR Life Sciences Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.7x15.5%
A245620 Eone Diagnomics Genome Center
0.8xn/aUS$41.47m
A215380 WOOJUNG BIO
0.6xn/aUS$20.09m
No more companies available in this PS range
A245620 0.8xIndustry Avg. 3.7xNo. of Companies7PS048121620+
2 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.7x27.1%
A245620 Eone Diagnomics Genome Center
0.8xn/aUS$41.47m
No more companies

Price-To-Sales vs Industry: A245620 is good value based on its Price-To-Sales Ratio (0.8x) compared to the KR Life Sciences industry average (3.9x).


Price to Sales Ratio vs Fair Ratio

What is A245620's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A245620 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A245620's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies